Table 1.
Characteristics of patients
| Characteristic | Primary Cohort (n=89) | Validation Cohort (n=41) | ||||
|---|---|---|---|---|---|---|
| Negative for LN Metastasis | Positive for LN Metastasis | P-Value | Negative for LN Metastasis | Positive for LN Metastasis | P-Value | |
| Age | 0.597 | 0.497 | ||||
| ≤ 60 y | 15 (53.6) | 32 (52.5) | 8 (66.7) | 4 (33.3) | ||
| > 60y | 29 (47.5) | 13 (46.4) | 16 (55.2) | 13 (44.8) | ||
| Gender | 0.063 | 0.853 | ||||
| Male | 21 (38.9) | 33 (61.1) | 12 (60.0) | 8 (40.0) | ||
| Female | 23 (65.7) | 12 (34.3) | 12 (57.1) | 9 (42.9) | ||
| CA19-9 | 0.054 | 0.577 | ||||
| ≥ 1000U/ml | 11 (35.5) | 20 (64.5) | 12 (63.2) | 7 (36.8) | ||
| < 1000U/ml | 33 (56.9) | 25 (43.1) | 12 (54.5) | 10 (45.5) | ||
| CEA | 0.057 | 0.680 | ||||
| ≥ 5 | 7 (31.8) | 15 (68.2) | 10 (62.5) | 6 (37.5) | ||
| <5 | 37 (55.2) | 30 (44.8) | 14 (56.0) | 11 (44.0) | ||
| CA12-5 | 0.145 | 0.500 | ||||
| ≥ 40 | 4 (30.8) | 9 (69.2) | 11 (64.7) | 6 (35.3) | ||
| <40 | 40 (52.6) | 36 (47.4) | 13 (54.2) | 11 (45.8) | ||
| CT-reported LN status | <0.05 | 0.292 | ||||
| 15 (78.9) | 4 (21.1) | 6 (75.5) | 2 (25.5) | |||
| 29 (41.4) | 41 (58.6) | 18 (54.5) | 15 (45.5) | |||
| Tumor size (>3cm) | <0.001 | 0.280 | ||||
| 24 (38.1) | 39 (61.9) | 18 (54.5) | 15 (45.5) | |||
| Vascular invasion | 0.275 | |||||
| 9 (32.1) | 19 (67.9) | <0.05 | 6 (46.2) | 7 (53.8) | ||
| Radscore* | <0.01 | <0.01 | ||||
| -0.23 (-0.45 to -0.04) | 0.14 (-0.05 to 0.45) | -0.0006 (-0.31 to 0.27) | 0.75 (0.01 to 1.01) | |||
Statistical analysis of patients with 95% CI; data in parentheses denotes percentages. CA19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; CA12-5: carbohydrate antigen 12-5. *Data in parentheses shows interquartile range.